Published in PLoS One on May 22, 2015
The MAGE protein family and cancer. Curr Opin Cell Biol (2015) 1.00
Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding. PLoS One (2016) 0.79
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. J Mol Biol (2017) 0.75
Biochemical and proteomic characterization of retrovirus Gag based microparticles carrying melanoma antigens. Sci Rep (2016) 0.75
The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling. Oncogene (2016) 0.75
The Magea gene cluster regulates male germ cell apoptosis without affecting the fertility in mice. Sci Rep (2016) 0.75
Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies. BMC Cancer (2017) 0.75
MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin. Cell Oncol (Dordr) (2017) 0.75
MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells. Oncogene (2017) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell (2010) 3.28
An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res (2001) 3.08
Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell (2004) 2.72
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ (2008) 2.36
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J (2006) 2.21
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res (2007) 2.08
DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem (2003) 2.03
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem (2003) 1.93
MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med (2012) 1.93
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 1.82
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A (2011) 1.66
Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol (2006) 1.61
The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res (2008) 1.53
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer (2009) 1.38
Melanoma-associated antigen genes - an update. Cancer Lett (2010) 1.36
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem (2011) 1.27
Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res (2010) 1.27
MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res (2004) 1.17
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res (2011) 1.14
The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta (2013) 1.12
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle (2008) 1.11
Mdm2 facilitates the association of p53 with the proteasome. Proc Natl Acad Sci U S A (2010) 1.11
MAGE-A antigens as targets in tumour therapy. Cancer Lett (2012) 1.10
Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res (2012) 1.07
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer (2012) 1.06
Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem (2009) 1.01
Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. J Biol Chem (2010) 1.00
Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1. J Mol Biol (2004) 1.00
When MAGE meets RING: insights into biological functions of MAGE proteins. Protein Cell (2011) 1.00
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem (2010) 0.97
MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ (2011) 0.96
MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression. PLoS One (2011) 0.93
Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer. Oncogene (2014) 0.91
Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene (2014) 0.91
It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53. Genes Cancer (2012) 0.83
aMAGEing new players enter the RING to promote ubiquitylation. Mol Cell (2010) 0.81